CELC

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Laing Lance G.Director, Officer: Chief Science Officer $200k20.3k shares Grant / ExerciseJun 2, 2026 $9.9K1k shares $9.89 --
Buller Richard EDirector --1k shares Grant / ExerciseMay 19, 2026 Disclosure amount unavailable1k shares -- --
Dalvey DavidDirector $9.1M65k shares SellMay 4, 2026 $3.5M25k shares $140.68 --
Buller Richard EDirector $1.0M7.1k shares SellMay 4, 2026 $401.3K2.8k shares $142.04 --
Buller Richard EDirector $1.4M10k shares SellMay 4, 2026 $324.5K2.3k shares $141.03 --
Buller Richard EDirector $1.7M12.3k shares SellMay 4, 2026 $233.1K1.7k shares $139.58 --

News

globenewswire.comCelcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032globenewswire.comJun 3

seekingalpha.comCelcuity: Selloff On Yesterday's Data Unwarranted - Buy Rating Upheldseekingalpha.comJun 3

globenewswire.comCelcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032globenewswire.comJun 3

Trade CELC

About Celcuity Inc.

Operating as a clinical-stage biotechnology company, Celcuity Inc. is dedicated to pioneering precision cancer treatments for patients across the United States. At the heart of their approach is the CELsignia diagnostic platform, which examines live tumor cells from patients. This innovative system aims to uncover the precise cellular dysfunction fueling an individual's cancer, thereby guiding the selection of the most appropriate targeted therapeutic intervention. Among its pipeline of drug candidates is Gedatolisib, an agent engineered to selectively inhibit class I PI3K isoforms and mammalian target of rapamycin (mTOR). This therapy is being developed specifically for advanced or metastatic breast cancer patients who are hormone receptor positive and HER2-negative. Celcuity is also advancing the CELsignia MP test, a qualitative lab-developed assay designed to quantify HER2, c-Met, and PI3K signaling activity within both breast and ovarian tumor cells. The company secured a licensing agreement with Pfizer, Inc. for the development and commercialization rights pertaining to Gedatolisib. Established in 2011, Celcuity Inc. maintains its corporate headquarters in Minneapolis, Minnesota.

CEO: Brian F. Sullivan
IPO Date: Sep 20, 2017

Market Data

Open: $90.51
High: $95.97
Low: $89.66
Volume: 701.2K
52W High: $151.02
52W Low: $11.28

Valuation

Market Cap: $4.4B
Enterprise Value: $4.4B

Financials

Free Cash Flow: $-154M
Revenue: $0
Net Income: $-177M
Cash: $166M
Debt: $195M

Events

EarningsAug 13

EPS est. -1.08